Xiao-Jun Ma
About Xiao-Jun Ma
CTO of Alamar Biosciences
Xiao-Jun Ma has been the Chief Technology Officer (CTO) of Alamar Biosciences since June 2021. His role involves overseeing technological advancements and strategic innovation within the company. With his extensive background, he plays a crucial part in driving the company's mission to develop cutting-edge solutions in the biosciences sector.
Over 20 Years of Experience in Life Sciences and Molecular Diagnostics
Xiao-Jun Ma possesses over two decades of experience in the life sciences and molecular diagnostics industries. His extensive expertise spans across various roles and companies, emphasizing his deep understanding and knowledge in these specialized fields. His contributions have significantly impacted technological advancements and research in these areas.
Former VP and Chief Scientific Officer at Bio-Techne's Genomics Division
Prior to his current role, Xiao-Jun Ma served as Vice President and Chief Scientific Officer in the Genomics Division of Bio-Techne. His leadership contributed to significant advancements in genomics, fostering the development of innovative research tools and diagnostic solutions.
Experience at Advanced Cell Diagnostics
During his 11-year tenure at Advanced Cell Diagnostics (ACD), Xiao-Jun Ma led the development of a world-leading portfolio of in situ RNA and DNA detection solutions. These solutions have been pivotal for both research and clinical diagnostics markets, showcasing his ability to drive innovative projects to fruition.
Educational Background in Biochemistry and Molecular Genetics
Xiao-Jun Ma received his doctorate training in biochemistry from Case Western Reserve University and the University of Iowa. He further enhanced his expertise with post-doctoral training in molecular genetics at the University of California, Los Angeles. This strong educational foundation has been instrumental in his successful career.
Roles at bioTheranostics, Johnson & Johnson, and Monsanto/Searle
Xiao-Jun Ma has held significant positions at various notable companies, including Vice President of R&D/Biostatistics at bioTheranostics, senior bioinformatics roles at Johnson & Johnson, and Monsanto/Searle (Pfizer). In these roles, he applied his multidisciplinary knowledge in molecular biology and bioinformatics to discover novel drug targets and biomarkers.